Caricamento quotazioni...
Previsioni
| Acquista |
1 |
| Mantieni |
0 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Biofrontera sells US license for Xepi to Pelthos Therapeutics for up to $10 million
Biofrontera has sold the US rights to the Xepi cream to Pelthos Therapeutics. The agreement foresees $3 million at signing, $1 million upon commercial availability and up to $6 million in revenue-dependent milestones (payments tied to $10 million and $15 million in annual sales in the USA, Puerto Rico and the US Virgin Islands). The company stresses the transaction strengthens the balance sheet and should secure financing until profitability; proceeds are to support growth of the photodynamic therapy platform and regulatory expansions for Ameluz. Biofrontera recently had more liquid assets than debt but a rapid cash burn; it also recently took over the US rights to Ameluz and RhodoLED and agreed an earn-out model. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | marzo 2026 | YoY |
|---|---|---|
| Ricavi | 3,71 Mln | - |
| Utile lordo | 3,01 Mln | - |
| Utile netto | 2,2 Mln | - |
| EBITDA | 106K | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 131,05 Mln € |
Numero di azioni | 44,57 Mln |
Massimo/minimo a 52 settimane | 5,30 € - 2,24 € |
| Dividendi | No |
Beta | -0,24 |
Rapporto P/E | -1,37 |
Rapporto PEG | -0,01 |
Rapporto P/B | 1,78 |
Rapporto P/S | 0,26 |
Profilo aziendale
| Nome | Biofrontera Aktie |
| CEO | Hermann Lübbert |
| Dipendenti | 82 |
